# AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

> **NCT00890825** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 88 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AZD6244
- **DRUG:** docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00890825
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-20
- **Primary completion:** 2011-05-11
- **Final completion:** 2016-11-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890825, "AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00890825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*